LipoCol Forte capsules reduce the risk of liver cancer: A propensity score-matched, nationwide, population-based cohort study

Table 4 Cox proportional hazard model estimated hazard ratio among cumulative dose of LipoCol Forte capsules

Variable	n	PY	IR	cHR	95%CI	P value	aHR1	95%CI	P value
Non-use of LFC as reference	3848	186604.2	20.6212	1.00	(Reference)	-	1.00	(Reference)	-
LFC dose (g)
< 91	3182	158379	20.09	0.94	(0.9, 0.98)b	0.0089	0.98	(0.94, 1.03)	0.4435
91-179	366	21568	16.97	0.77	(0.69, 0.86)c	<0.001	0.69	(0.62, 0.77)c	< 0.001
> 179	152	12175	12.48	0.55	(0.47, 0.65)c	<0.001	0.46	(0.39, 0.55)c	< 0.001

¹Adjusted in multivariate analysis by sex, age, comorbidities and medications.

^aP < 0.05.

^bP < 0.01.

^cP < 0.001.

LFC: LipoCol Forte capsules; PY: Person-years; IR: Incidence rate per 1000 person-years; cHR: Crude hazard ratio; aHR: Adjusted hazard ratio.